Left ventricular hypertrophy: why does it happen?
|
|
- Darlene Fox
- 6 years ago
- Views:
Transcription
1 Nephrol Dial Transplant (2003) 18 [Suppl 8]: viii2 viii6 DOI: /ndt/gfg1083 Left ventricular hypertrophy: why does it happen? Gerard M. London Department of Nephrology and Dialysis, Manhes Hospital, Fleury Me rogis, France Abstract Patients with end-stage renal disease (ESRD) have much higher rates of cardiovascular disease than the healthy population. Left ventricular hypertrophy (LVH), in particular, is common in this patient group. The impact of a decline in haemoglobin concentration on left ventricular mass index has been well documented. Partial correction of anaemia with recombinant human erythropoietin (epoetin) treatment has been recognized as a significant step forward in decreasing left ventricular mass and improving cardiovascular morbidity and mortality. However, LVH and cardiac failure in patients with ESRD comprise a complex condition, which is influenced by a number of factors in addition to anaemia. This article examines some of the pathophysiological aspects of LVH in patients with ESRD. Keywords: anaemia; chronic renal failure; end-stage renal disease; epoetin; left ventricular hypertrophy; pathophysiology Introduction Cardiovascular disease is the leading cause of death in patients with end-stage renal disease (ESRD). The prevalence of coronary artery disease is 40% in these patients, which is much higher than in the general population (Table 1) [1]. Cardiovascular mortality in haemodialysis (HD) and peritoneal dialysis patients has been estimated to be 9% per year. The most common cardiac anomaly in ESRD is left ventricular hypertrophy (LVH), which has been observed in 75% of patients at the start of dialysis [1]. The prevalence of LVH is related to the degree of renal insufficiency [2]. LVH is an ominous prognostic sign that may result in Correspondence and offprint requests to: G. M. London, MD, Department of Nephrology and Dialysis, Manhes Hospital, Fleury-Mérogis, 8 grande rue, F-91712, France. glondon@ club-internet.fr systolic and/or diastolic dysfunction and is an independent risk factor for arrhythmias, sudden death, heart failure and myocardial ischaemia [3,4]. Pathogenesis of cardiac disease in chronic renal failure LVH and cardiac failure are adaptive responses to increased cardiac work, which is the product of left ventricular pressure and stroke volume. Combined volume and pressure overload is the primary cause of LVH in patients with ESRD. This is exacerbated by a number of other factors including gender, age, renin angiotensin aldosterone system (RAAS) activity, level of oxidative stress, etc. There is a close relationship between changes in the stroke work index and left ventricular mass in patients with ESRD [5]. Stroke work is related to the changes in ventricular volume (stroke volume) and the changes in mean systolic pressure in the left ventricle. These factors are the principal determinants of left ventricular mass. Increased left ventricular mass is frequently seen in individuals such as highly trained athletes (longdistance runners, cyclists), during pregnancy and physiologically also with growth from infancy to adulthood. In these cases, it is a normal compensatory physiological mechanism and is reversible. The rise in the number of sarcomeres and the increase in wall thickness increase the working capacity of the left ventricle, while keeping parietal tensile stress stable and thus sparing energy. This allows the heart to maintain normal systolic function during the phase of compensated (adaptive) hypertrophy. LVH that is accompanied by the serious complication of fibrosis, however, leads to abnormal function and stiffness. Fibrosis is observed when volume or pressure overload is associated with non-haemodynamic factors such as the RAAS, local inflammation and ischaemia. Sustained overload leads progressively to maladaptive hypertrophy, which is characterized by the development of cardiomyopathy of overload and heart failure. ß 2003 European Renal Association European Dialysis and Transplant Association
2 Left ventricular hypertrophy: why does it happen? In the maladaptive phase, energy expenditure by the overloaded myocardial cells exceeds energy production, resulting in a chronic energy deficit and myocyte death. Cell proliferation and differentiation of non-myocytes, especially cardiac fibroblasts, is thought to be abnormal in chronic energy deficit. There is a rapid increase in collagen synthesis and a disproportionate increase in the extracellular matrix. These responses allow the mechanical efficiency of the contraction of the heart to be maintained, at the expense of impaired diastolic filling. Patterns of hypertrophy The relationship between pressure and volume overload influences the type of subsequent LVH (Figure 1). If the primary stimulus is volume overload, there is an Table 1. Approximate prevalence of cardiovascular disease by target population CAD (%) clinical LVH (%) echo General population Chronic renal failure N/A Haemodialysis Peritoneal dialysis Renal transplant recipients CAD, coronary artery disease; LVH, left ventricular hypertrophy. viii3 increase in diastolic pressure and stress, which initially causes the addition of new sarcomeres in series, followed by new sarcomeres in parallel. LVH termed eccentric hypertrophy develops with an increased wall thickness that is just sufficient to counterbalance the increased radius. In these patients, the relative wall thickness (wall thickness [h]/ventricle radius [r]) is <0.45 as is also seen in those patients with healthy ventricles. If the primary stimulus is pressure overload, then LVH is related to systolic or pulse pressure (see Figure 1). Arterial stiffness determines the pulse pressure amplitude and the propagative properties of the arterial system, which in turn determine the speed of the pressure wave and the timing of the wave reflected from peripheral sites. Pressure overload results in the parallel addition of new sarcomeres, with a disproportionate increase in ventricular wall thickness at normal chamber radius. This is termed concentric hypertrophy as the left ventricle does not change its internal dimensions. In these patients, the relative wall thickness is >0.45 as the ventricle does not increase in radius despite an increase in wall thickness. Haemodynamic overload and cardiac hypertrophy in ESRD The relationship between volume overload and pressure overload in patients with ESRD is complex. Volume overload in patients receiving HD is associated Fig. 1. Hypothesis relating wall stress and patterns of hypertrophy. Adapted, with permission from Excerpta Medica Inc., from Grossman [6].
3 viii4 with the presence of an arteriovenous fistula, which may result in an increase of up to 25% in cardiac output. In addition, the presence of intermittent sodium and water retention and associated chronic anaemia is responsible for increased stroke volume and increased heart rate. Anaemia is already present in the majority of patients initiating HD and is probably the most important factor in explaining why 75% of these patients have LVH. Pressure overload is associated with hypertension, principally in pre-dialysis patients, with arteriosclerosis that is related in part to calcification, and to aortic stenosis. The impact of decreasing left ventricular mass Early work published by Silberberg et al. showed that LVH is associated with poor outcome in patients with ESRD [7]. This study showed that LVH is an important, independent determinant of survival in these patients. It also suggested that if left ventricular mass could be decreased in these patients, it might result in improved survival rates. Anaemia, hypertension and the presence of an arteriovenous fistula were all considered to be important contributors to LVH in ESRD. Anaemia was suggested as being of primary importance because this can be treated effectively with recombinant human erythropoietin (epoetin). Another, more recent observational study in 150 patients with 5 years of follow-up showed that those patients who responded to treatment for anaemia and high blood pressure that resulted in a decrease in ventricular mass had statistically significant improved survival rates, compared with non-responders (Figure 2) [8]. LVH was present in 90% of these patients with ESRD receiving HD and partial LVH regression had a favourable and independent effect on G. M. London their survival. The study demonstrated that attenuation of haemodynamic overload reduced LVH and that a reduction of LVH was a favourable prognostic marker, which predicted a lower risk for subsequent non-fatal cardiovascular morbid events. One of the reasons why LVH is an independent risk factor for mortality in patients with ESRD is that it decreases the coronary reserve as more blood is required for perfusion. Haemodynamic changes induced by anaemia The relationship between anaemia and left ventricular mass is now well known. Anaemia is responsible for a chronic increase in cardiac output and chronic volume overload (Figure 3). One result of anaemia is the decrease in erythrocyte mass and blood viscosity. This in turn decreases peripheral resistance, which results in increased venous return and cardiac output. Another result is that oxygen delivery is reduced leading to recruitment of vessels and angiogenesis in chronic conditions with a resulting increase in heart rate and cardiac output. In addition, it is hypothesized that the presence of a low haemoglobin (Hb) concentration results in a higher availability of endothelium-derived relaxing factor (nitric oxide), which leads to vessel dilatation and increased cardiac output. The benefits of treating anaemia in ESRD patients Treating anaemia improves the cardiac status of patients with ESRD. A consistent finding in different groups worldwide is that partial correction of Hb concentration results in partial regression of LVH. Treatment of pre-dialysis patients with epoetin partially corrects anaemia and induces left ventricular mass Fig. 2. Probability of cardiovascular survival in ESRD patients whose LV mass decreased (responders) and in those in whom it did not change or increased (non-responders).
4 Left ventricular hypertrophy: why does it happen? viii5 Fig. 3. Haemodynamic changes induced by anaemia. index regression without improvements in blood pressure control [9]. Improving anaemia also improves cardiac status and function, even in patients with congestive heart failure [10], although there are many other factors that influence the growth of left ventricular mass. The importance of systolic pressure and pulse wave velocity Pressure overload is measured in terms of systolic or diastolic blood pressure. Systolic pressure related to arterial stiffening is much more important than diastolic pressure in these patients and there is a significant relationship between systolic blood pressure and end-organ damage. Diastolic pressure is usually normal in these patients with ESRD. Therefore, in the presence of systolic hypertension and a stiff arterial system, coronary perfusion is low and the load imposed on the left ventricle is high. Pulse pressure is an independent predictor of mortality in the general population and is increased in patients with ESRD in association with increased arterial stiffness and a pronounced effect of arterial wave reflections. Pulse pressure is determined by the interaction of cardiac factors (stroke volume and ejection time) and vascular factors (arterial stiffness and arterial wave reflections). Pulse wave velocity is perhaps a more accurate means of measuring pressure overload than measuring systolic hypertension itself. There is a close relationship between aortic pulse wave velocity and left ventricular mass index [11]. High pulse wave velocity is associated with increased aortic stiffness and increased LVH. A recent study has shown that aortic stiffening, determined by measurement of aortic pulse wave velocity, was an independent predictor of all-cause and cardiovascular mortality in patients with ESRD [12]. Although treatment of anaemia has already been shown to produce a partial regression of LVH, which improves the mechanical properties of the aorta, microinflammation has also been shown to have a significant influence [7]. There is a significant independent relationship between serum C-reactive protein level and aortic stiffness in patients with ESRD [13]. In the presence of micro-inflammation, there is resistance to epoetin treatment and other antihypertensive drugs, which illustrates the complexity of the mechanisms of LVH. A recent study has provided direct evidence that the increased effect of arterial wave reflections, independent of arterial stiffness, blood pressure and other cardiovascular risk factors, is a significant predictor of all-cause mortality and cardiovascular mortality in patients with ESRD [14]. This study showed that cardiovascular mortality in patients with ESRD is dependent on a number of factors including high aortic pressure wave velocity, wave reflection, prior cardiovascular disease and low diastolic blood pressure. Conclusion Anaemia is a significant factor affecting LVH in patients with ESRD, and treatment of anaemia with epoetin has been shown to induce a partial regression of left ventricular mass. However, there are many other factors, including micro-inflammation, which influence this condition and require further study.
5 viii6 References 1. Foley RN, Parfrey PS, Sarnak M. Cardiovascular disease in chronic renal disease: clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32 [Suppl 3]: S112 S Levin A, Thompson CR, Ethier J et al. Left ventricular mass index increase in early renal disease: impact of decline in haemoglobin. Am J Kidney Dis 1999; 34: Harnett JD, Kent GM, Barre PE et al. Risk factors for the development of left ventricular hypertrophy in a prospective cohort of dialysis patients. J Am Soc Nephrol 1994; 4: Parfrey PS, Foley RN, Harnett JD et al. Outcome and risk factors for left ventricular disorders in chronic uremia. Nephrol Dial Transplant 1996; 11: London GM, Guérin AP, Marchais SJ. Hemodynamic overload in end-stage renal disease. Seminar Dial 1999; 12: Grossman W. Cardiac hypertrophy: useful adaptation or pathologic process? Am J Med 1980; 69: Silberberg JS, Barre P, Prichard S, Sniderman A. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 1989; 36: G. M. London 8. London GM, Pannier B, Guerin AP et al. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow up of an interventional study. J Am Soc Nephrol 2001; 12: Portoles J, Torralbo A, Martin P et al. Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis 1997; 29: Silverberg D, Wexler D, Blum M, Iaina A. The cardio renal syndrome: does it exist? Nephrol Dial Transplant 2003; 18 [Suppl 8]: viii7 viii London GM, Zins B, Pannier B et al. Vascular changes in hemodialysis patients in response to recombinant human erythropoietin. Kidney Int 1989; 36: Blacher J, Guerin AP, Pannier B et al. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999; 99: London GM, Marchais SJ, Guérin AP et al. Inflammation, arteriosclerosis, and cardiovascular therapy in hemodialysis patients. Kidney Int 2003; 3 [Suppl 84]: S88 S London GM, Blacher J, Pannier B et al. Arterial wave reflections and survival in end-stage renal failure. Hypertension 2001; 38:
Benefits from angiotensin-converting enzyme inhibition in patients with renal failure: latest results
European Heart Journal Supplements (2003) 5 (Supplement E), E18 E22 Benefits from angiotensin-converting enzyme inhibition in patients with renal failure: latest results B. Pannier, A.P. Guérin, S.J. Marchais
More informationHTA ET DIALYSE DR ALAIN GUERIN
HTA ET DIALYSE DR ALAIN GUERIN Cardiovascular Disease Mortality General Population vs ESRD Dialysis Patients 100 Annual CVD Mortality (%) 10 1 0.1 0.01 0.001 25-34 35-44 45-54 55-64 66-74 75-84 >85 Age
More informationA rationale for an individualized haemoglobin target
Nephrol Dial Transplant (2002) 17 [Suppl 6 ]: 2 7 A rationale for an individualized haemoglobin target Norman Muirhead University of Western Ontario, London, Ontario, Canada Abstract Despite the use of
More informationLeft ventricular alterations and end-stage renal disease
Nephrol Dial Transplant (2002) 17 wsuppl 1x: 29 36 Left ventricular alterations and end-stage renal disease Gerard M. London Centre Hospitalier FH MANHES, Fleury-Mérogis, France Abstract The prevalence
More informationBecause of important technologic advances achieved over
Anemia and Heart Failure in Chronic Kidney Disease Francesco Locatelli, Pietro Pozzoni, and Lucia Del Vecchio Cardiovascular disease is mainly responsible for the poor long-term survival observed in chronic
More informationCardiovascular Disease in CKD. Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center
Cardiovascular Disease in CKD Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center Objectives Describe prevalence for cardiovascular disease in CKD
More informationPrevalence of cardiovascular damage in early renal disease
Nephrol Dial Transplant 2001) 16 wsuppl 2x: 7±11 Prevalence of cardiovascular damage in early renal disease Adeera Levin University of British Columbia, Renal Insuf ciency Clinic, Vancouver, Canada Abstract
More informationReview of Cardiac Imaging Modalities in the Renal Patient. George Youssef
Review of Cardiac Imaging Modalities in the Renal Patient George Youssef ECHO Left ventricular hypertrophy (LVH) assessment Diastolic dysfunction Stress ECHO Cardiac CT angiography Echocardiography - positives
More informationIn Vivo Animal Models of Heart Disease. Why Animal Models of Disease? Timothy A Hacker, PhD Department of Medicine University of Wisconsin-Madison
In Vivo Animal Models of Heart Disease Timothy A Hacker, PhD Department of Medicine University of Wisconsin-Madison Why Animal Models of Disease? Heart Failure (HF) Leading cause of morbidity and mortality
More informationSelected age-associated changes in the cardiovascular system
Selected age-associated changes in the cardiovascular system Tamara Harris, M.D., M.S. Chief, Interdisciplinary Studies of Aging Acting Co-Chief, Laboratory of Epidemiology and Population Sciences Intramural
More informationThe organs of the human body were created to perform ten functions among which is the function of the kidney to furnish the human being with thought.
The organs of the human body were created to perform ten functions among which is the function of the kidney to furnish the human being with thought. Leviticus Rabba 3 Talmud Berochoth 6 1 b Outline &
More informationOn Referral to our Unit
Case Presentation By Samah Ibrahim Abdel Meguid Idris, MD Internal Medicine & Nephrology Consultant Head of Hemodialysis Unit Ahmed Maher Hospital, Alexandria Patient Data MEA 27-year-old male patient
More informationDoppler ultrasound, see Ultrasonography. Magnetic resonance imaging (MRI), kidney oxygenation assessment 75
Subject Index Acidemia, cardiorenal syndrome type 3 146 Acute Dialysis Quality Initiative (ADQI) acute kidney injury biomarkers, see Acute kidney injury; specific biomarkers cardiorenal syndrome, see specific
More informationImproved Assessment of Aortic Calcification in Japanese Patients Undergoing Maintenance Hemodialysis
ORIGINAL ARTICLE Improved Assessment of Aortic Calcification in Japanese Patients Undergoing Maintenance Hemodialysis Masaki Ohya 1, Haruhisa Otani 2,KeigoKimura 3, Yasushi Saika 4, Ryoichi Fujii 4, Susumu
More informationEffects of Kidney Disease on Cardiovascular Morbidity and Mortality
Effects of Kidney Disease on Cardiovascular Morbidity and Mortality Joachim H. Ix, MD, MAS Assistant Professor in Residence Division of Nephrology University of California San Diego, and Veterans Affairs
More informationAge-related changes in cardiovascular system. Dr. Rehab Gwada
Age-related changes in cardiovascular system Dr. Rehab Gwada Objectives explain the main structural and functional changes in cardiovascular system associated with normal aging Introduction aging results
More informationHYPERTENSION AND HEART FAILURE
HYPERTENSION AND HEART FAILURE Kenya Cardiac Society Symposium Feb 2017 Dr Jeilan Mohamed No conflict of interests . Geoffrey, 45 yr old hypertensive office worker male from Nairobi, has just watched his
More informationNephrology Dialysis Transplantation
Nephrol Dial Transplant (1999) 14 [Suppl 2]: 29 36 Chairman s Workshop Report Nephrology Dialysis Transplantation What are the short-term and long-term consequences of anaemia in CRF patients? Department
More informationAssessment of Arterials Functions: Is Pulse Wave Velocity ready forprime Time. Gérard M. LONDON INSERM U970 Hopital Georges Pompidou Paris, France
Assessment of Arterials Functions: Is Pulse Wave Velocity ready forprime Time Gérard M. LONDON INSERM U970 Hopital Georges Pompidou Paris, France The causes of Cardiovascular Diseases in CKD Systolic BP;
More informationClinical application of Arterial stiffness. pulse wave analysis pulse wave velocity
Clinical application of Arterial stiffness pulse wave analysis pulse wave velocity Arterial system 1. Large arteries: elastic arteries Aorta, carotid, iliac, Buffering reserve: store blood during systole
More informationPublished trials point to a detrimental relationship
ANEMIA, CHRONIC KIDNEY DISEASE, AND CARDIOVASCULAR DISEASE: THE CLINICAL TRIALS Steven Fishbane, MD* ABSTRACT Clinical trials have shown a strong detrimental relationship among anemia, chronic kidney disease
More informationCopyright 2011, 2007 by Mosby, Inc., an affiliate of Elsevier Inc. Normal Cardiac Anatomy
Mosby,, an affiliate of Elsevier Normal Cardiac Anatomy Impaired cardiac pumping Results in vasoconstriction & fluid retention Characterized by ventricular dysfunction, reduced exercise tolerance, diminished
More informationDevelopment, Prevention, and Potential Reversal of Left Ventricular Hypertrophy in Chronic Kidney Disease
J Am Soc Nephrol 15: 1640 1647, 2004 Development, Prevention, and Potential Reversal of Left Ventricular Hypertrophy in Chronic Kidney Disease LAWRENCE P. MCMAHON,* SIMON D. ROGER, and ADEERA LEVIN, FOR
More informationLV geometric and functional changes in VHD: How to assess? Mi-Seung Shin M.D., Ph.D. Gachon University Gil Hospital
LV geometric and functional changes in VHD: How to assess? Mi-Seung Shin M.D., Ph.D. Gachon University Gil Hospital LV inflow across MV LV LV outflow across AV LV LV geometric changes Pressure overload
More informationStructural abnormalities of the heart and vascular system in CKD & Dialysis - Thick but weak
Structural abnormalities of the heart and vascular system in CKD & Dialysis - Thick but weak Kerstin Amann Nephropathology, Dept. of Pathology, University of Erlangen-Nürnberg Krankenhausstr. 8-10 91054
More informationPublished trials point to a detrimental relationship
ANEMIA, CHRONIC KIDNEY DISEASE, AND CARDIOVASCULAR DISEASE: THE CLINICAL TRIALS Steven Fishbane, MD* ABSTRACT Clinical trials have shown a strong detrimental relationship among anemia, chronic kidney disease
More informationIn the name of GOD. Animal models of cardiovascular diseases: myocardial infarction & hypertension
In the name of GOD Animal models of cardiovascular diseases: myocardial infarction & hypertension 44 Presentation outline: Cardiovascular diseases Acute myocardial infarction Animal models for myocardial
More informationPathophysiology: Heart Failure
Pathophysiology: Heart Failure Mat Maurer, MD Irving Assistant Professor of Medicine Outline Definitions and Classifications Epidemiology Muscle and Chamber Function Pathophysiology Heart Failure: Definitions
More informationEchocardiography analysis in renal transplant recipients
Original Research Article Echocardiography analysis in renal transplant recipients S.A.K. Noor Mohamed 1*, Edwin Fernando 2, 1 Assistant Professor, 2 Professor Department of Nephrology, Govt. Stanley Medical
More informationCardiovascular Mortality: General Population vs ESRD Dialysis Patients
Cardiovascular Mortality: General Population vs ESRD Dialysis Patients Annual CVD Mortality (%) 100 10 1 0.1 0.01 0.001 25-34 35-44 45-54 55-64 66-74 75-84 >85 Age (years) GP Male GP Female GP Black GP
More informationLEFT VENTRICULAR HYPERTROPHY AND CLINICAL OUTCOME IN CAPD PATIENTS
Peritoneal Dialysis International, Vol. 20, pp. 461 466 Printed in Canada. All rights reserved. 0896-8608/00 $3.00 +.00 Copyright 2000 International Society for Peritoneal Dialysis LEFT VENTRICULAR HYPERTROPHY
More informationEffects of Renin-Angiotensin System blockade on arterial stiffness and function. Gérard M. LONDON Manhès Hospital Paris, France
Effects of Renin-Angiotensin System blockade on arterial stiffness and function Gérard M. LONDON Manhès Hospital Paris, France Determinants of vascular overload (afterload) on the heart Peripheral Resistance
More informationSkin supplied by T1-4 (medial upper arm and neck) T5-9- epigastrium Visceral afferents from skin and heart are the same dorsal root ganglio
Cardio 2 ECG... 3 Cardiac Remodelling... 11 Valvular Diseases... 13 Hypertension... 18 Aortic Coarctation... 24 Erythropoiesis... 27 Haemostasis... 30 Anaemia... 36 Atherosclerosis... 44 Angina... 48 Myocardial
More informationEjection across stenotic aortic valve requires a systolic pressure gradient between the LV and aorta. This places a pressure load on the LV.
Valvular Heart Disease Etiology General Principles Cellular and molecular mechanism of valve damage Structural pathology Functional pathology - stenosis/regurgitation Loading conditions - pressure/volume
More informationLong-term blood pressure monitoring and echocardiographic findings in patients with end-stage renal disease: reverse epidemiology explained?
O R I G I N A L A R T I C L E Long-term blood pressure monitoring and echocardiographic findings in patients with end-stage renal disease: reverse epidemiology explained? H. Borsboom 1#, L. Smans 1#, M.J.M.
More informationLong-term evolution of cardiomyopathy in dialysis patients
Kidney International, Vol. 54 (1998), pp. 1720 1725 Long-term evolution of cardiomyopathy in dialysis patients ROBERT N. FOLEY, PATRICK S. PARFREY, GLORIA M. KENT, JOHN D. HARNETT, DAVID C. MURRAY, and
More informationEjection across stenotic aortic valve requires a systolic pressure gradient between the LV and aorta. This places a pressure load on the LV.
Valvular Heart Disease General Principles Etiology Cellular and molecular mechanism of valve damage Structural pathology Functional pathology - stenosis/regurgitation Loading conditions - pressure/volume
More informationEchocardiographic assessment of left ventricular hypertrophy in patients of chronic kidney disease
International Journal of Research in Medical Sciences Behera BK et al. Int J Res Med Sci. 2017 Nov;5(11):4783-4788 www.msjonline.org pissn 2320-6071 eissn 2320-6012 Original Research Article DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20174672
More informationStructure and organization of blood vessels
The cardiovascular system Structure of the heart The cardiac cycle Structure and organization of blood vessels What is the cardiovascular system? The heart is a double pump heart arteries arterioles veins
More informationCardiovascular Complications Of Chronic Kidney Disease. Dr Atir Khan Consultant Physician Diabetes & Endocrinology West Wales Hospital, Carmarthen
Cardiovascular Complications Of Chronic Kidney Disease Dr Atir Khan Consultant Physician Diabetes & Endocrinology West Wales Hospital, Carmarthen Markers of kidney dysfunction Raised Albumin / Creatinine
More informationPathophysiology: Heart Failure. Objectives
Pathophysiology: Heart Failure Mat Maurer, MD Irving Assistant Professor of Clinical Medicine Objectives At the conclusion of this seminar, learner will be able to: 1. Define heart failure as a clinical
More informationCardiovascular Diseases before and after Renal Transplantation
Med. J. Cairo Univ., Vol. 84, No. 1, June: 409-415, 2016 www.medicaljournalofcairouniversity.net Cardiovascular Diseases before and after Renal Transplantation TAREK H. EL-SHABONY, M.D.*; HUSSEIN M. HESHMATE,
More informationOutline. Pathophysiology: Heart Failure. Heart Failure. Heart Failure: Definitions. Etiologies. Etiologies
Outline Pathophysiology: Mat Maurer, MD Irving Assistant Professor of Medicine Definitions and Classifications Epidemiology Muscle and Chamber Function Pathophysiology : Definitions An inability of the
More informationAllopurinol reduces left ventricular hypertrophy and endothelial dysfunction in patients with chronic kidney disease
Allopurinol reduces left ventricular hypertrophy and endothelial dysfunction in patients with chronic kidney disease Michelle P Kao, Donald S Ang, Steve Gandy, Chim C Lang, Allan D Struthers Division of
More informationSpecial Lecture 11/08/2013. Hypertension Dr. HN Mayrovitz
Special Lecture 11/08/2013 Hypertension Dr. HN Mayrovitz Arterial Blood Pressure (ABP) Major Factors Summarized Sympathetic Hormones Arteriole MAP ~ Q x TPR + f (V / C) SV x HR Renal SBP Hypertension =
More informationHeart Failure. Cardiac Anatomy. Functions of the Heart. Cardiac Cycle/Hemodynamics. Determinants of Cardiac Output. Cardiac Output
Cardiac Anatomy Heart Failure Professor Qing ZHANG Department of Cardiology, West China Hospital www.blaufuss.org Cardiac Cycle/Hemodynamics Functions of the Heart Essential functions of the heart to cover
More informationLab Period: Name: Physiology Chapter 14 Blood Flow and Blood Pressure, Plus Fun Review Study Guide
Lab Period: Name: Physiology Chapter 14 Blood Flow and Blood Pressure, Plus Fun Review Study Guide Main Idea: The function of the circulatory system is to maintain adequate blood flow to all tissues. Clinical
More informationDiastology State of The Art Assessment
Diastology State of The Art Assessment Dr. Mohammad AlGhamdi Assistant professor, KSAU-HS Consultant Cardiologist King AbdulAziz Cardiac Center Ministry of National Guard Health Affairs Diagnostic Clinical
More informationHeart Failure (HF) Treatment
Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and
More informationEnd stage renal disease (ESRD) is the irreversible deterioration of renal function
28 Journal of the association of physicians of india JANUARY 2014 VOL. 62 Original Article Echocardiographic Assessment of Cardiac Dysfunction in Patients of End Stage Renal Disease on Haemodialysis Mukesh
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Serum phosphate GUIDELINES
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Serum phosphate GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL CARE (Suggestions
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Biochemical Targets. Calcium GUIDELINES
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Biochemical Targets CARMEL HAWLEY (Woolloongabba, Queensland) GRAHAME ELDER (Westmead, New South Wales) Calcium GUIDELINES
More informationEchocardiographic Assessment of Cardiac Dysfunction in Patients of Chronic Renal Failure
ORIGINAL ARTICLE JIACM 2003; 4(4): 296-303 Echocardiographic Assessment of Cardiac Dysfunction in Patients of Chronic Renal Failure Abstract S Agarwal*, P Dangri**, OP Kalra***, S Rajpal**** Objective
More informationThe Causes of Heart Failure
The Causes of Heart Failure Andy Birchall HFSN Right heart failure LVSD - HFREF Valve regurgitation or stenosis Dropsy CCF congestive cardiac failure Cor pulmonale Pulmonary hypertension HFPEF LVF Definitions
More informationHeart Failure. Acute. Plasma [NE] (pg/ml) 24 Hours. Chronic
Heart Failure Heart failure is the inability of the heart to deliver sufficient blood to the tissues to ensure adequate oxygen supply. Clinically it is characterized by signs of volume overload or symptoms
More informationHEART FAILURE PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
HEART FAILURE PHARMACOLOGY University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 LEARNING OBJECTIVES Understand the effects of heart failure in the body
More informationCirculation. Blood Pressure and Antihypertensive Medications. Venous Return. Arterial flow. Regulation of Cardiac Output.
Circulation Blood Pressure and Antihypertensive Medications Two systems Pulmonary (low pressure) Systemic (high pressure) Aorta 120 mmhg Large arteries 110 mmhg Arterioles 40 mmhg Arteriolar capillaries
More informationProf. Andrzej Wiecek Department of Nephrology, Endocrinology and Metabolic Diseases Medical University of Silesia Katowice, Poland.
What could be the role of renal denervation in chronic kidney disease? Andrzej Wiecek, Katowice, Poland Chairs: Peter J. Blankestijn, Utrecht, The Netherlands Jonathan Moss, Glasgow, UK Prof. Andrzej Wiecek
More informationAortic regurgitation. Physiopathology. Dr Pilar Tornos Hospital Vall d Hebron. Barcelona Eurovalve 2014
Aortic regurgitation. Physiopathology Dr Pilar Tornos Hospital Vall d Hebron. Barcelona Eurovalve 2014 Faculty disclosure Pilar Tornos I have no financial relationships to disclose. Acute AR Etiology:
More informationMaher Fouad Ramzy; MD, FACP Professor of Renal Medicine, Cairo University
Hypertension in Hemodialysis Patient Maher Fouad Ramzy; MD, FACP Professor of Renal Medicine, Cairo University Mechanism of HTN in HD patients Volume-dependent HTN ECV expansion. Volume-independent HTN
More informationMeans failure of heart to pump enough blood to satisfy the need of the body.
Means failure of heart to pump enough blood to satisfy the need of the body. Due to an impaired ability of the heart to adequately to fill or eject blood. HEART FAILURE Heart failure (HF) means decreased
More informationCardiac Output MCQ. Professor of Cardiovascular Physiology. Cairo University 2007
Cardiac Output MCQ Abdel Moniem Ibrahim Ahmed, MD Professor of Cardiovascular Physiology Cairo University 2007 90- Guided by Ohm's law when : a- Cardiac output = 5.6 L/min. b- Systolic and diastolic BP
More informationEpidemiological and clinical studies have shown that
Impact of Aortic Stiffness Attenuation on Survival of Patients in End-Stage Renal Failure Alain P. Guerin, MD; Jacques Blacher, MD, PhD; Bruno Pannier, MD; Sylvain J. Marchais, MD; Michel E. Safar, MD;
More informationTopic Page: congestive heart failure
Topic Page: congestive heart failure Definition: congestive heart f ailure from Merriam-Webster's Collegiate(R) Dictionary (1930) : heart failure in which the heart is unable to maintain an adequate circulation
More informationCardiology. the Sounds: #7 HCM. LV Outflow Obstruction: Aortic Stenosis. (Coming Soon - HCM)
A Cardiology HCM LV Outflow Obstruction: Aortic Stenosis (Coming Soon - HCM) the Sounds: #7 Howard J. Sachs, MD www.12daysinmarch.com E-mail: Howard@12daysinmarch.com Aortic Valve Disorders Stenosis Regurgitation
More informationArterial Pressure in CKD5 - ESRD Population Gérard M. London
Arterial Pressure in CKD5 - ESRD Population Gérard M. London INSERM U970 Paris 150 SBP & DBP by Age, Ethnicity &Gender (US Population Age 18 Years, NHANES III) 150 SBP (mm Hg) 130 110 80 Non-Hispanic Black
More informationPRELIMINARY STUDIES OF LEFT VENTRICULAR WALL THICKNESS AND MASS OF NORMOTENSIVE AND HYPERTENSIVE SUBJECTS USING M-MODE ECHOCARDIOGRAPHY
Malaysian Journal of Medical Sciences, Vol. 9, No. 1, January 22 (28-33) ORIGINAL ARTICLE PRELIMINARY STUDIES OF LEFT VENTRICULAR WALL THICKNESS AND MASS OF NORMOTENSIVE AND HYPERTENSIVE SUBJECTS USING
More informationChapter 9. Body Fluid Compartments. Body Fluid Compartments. Blood Volume. Blood Volume. Viscosity. Circulatory Adaptations to Exercise Part 4
Body Fluid Compartments Chapter 9 Circulatory Adaptations to Exercise Part 4 Total body fluids (40 L) Intracellular fluid (ICF) 25 L Fluid of each cell (75 trillion) Constituents inside cell vary Extracellular
More informationImproving Transition of Care in Congestive Heart Failure. Mark J. Gloth, DO, MBA. Vice President, Chief Medical Officer HCR ManorCare
Improving Transition of Care in Congestive Heart Failure Mark J. Gloth, DO, MBA. Vice President, Chief Medical Officer HCR ManorCare Heart Failure Fastest growing clinical cardiac disease in the United
More informationCardiovascular Diseases in CKD
1 Cardiovascular Diseases in CKD Hung-Chun Chen, MD, PhD. Kaohsiung Medical University Taiwan Society of Nephrology 1 2 High Prevalence of CVD in CKD & ESRD Foley RN et al, AJKD 1998; 32(suppl 3):S112-9
More informationPatients with chronic kidney disease (CKD) are
CLINICAL INTERVENTIONS TO REDUCE CARDIOVASCULAR RISK IN PATIENTS WITH KIDNEY DISEASE Jeffrey S. Berns, MD* ABSTRACT Although the specific mechanisms by which chronic kidney disease (CKD) and cardiovascular
More informationΗ σημασία της αρτηριακής σκληρίας στην εκτίμηση της διαστολικής δυσλειτουργίας στην υπέρταση. Θεραπευτικές παρεμβάσεις
Η σημασία της αρτηριακής σκληρίας στην εκτίμηση της διαστολικής δυσλειτουργίας στην υπέρταση. Θεραπευτικές παρεμβάσεις Ελένη Τριανταφυλλίδη Επιμελήτρια Α Β Πανεπιστημιακή Καρδιολογική Κλινική Αττικό Νοσοκομείο
More informationRisk Factors in the Progression of Chronic Kidney Disease
Risk Factors in the Progression of Chronic Kidney Disease a report by Rainer Düsing Professor, Faculty of Medicine, University of Bonn DOI:10.17925/EE.2006.00.02.1e Chronic kidney disease (CKD) is a complex,
More informationDIASTOLIC HEART FAILURE
DIASTOLIC HEART FAILURE M Mohsen Ibrahim, MD Alexandria, Proposed Criteria for Diastolic Heart Failure ESC Working Group (EHJ 1998) CHF signs/symptoms EF 45% Hemodynamic or echo evidence of diastolic dysfunction
More informationCardiovascular Physiology
Cardiovascular Physiology Lecture 1 objectives Explain the basic anatomy of the heart and its arrangement into 4 chambers. Appreciate that blood flows in series through the systemic and pulmonary circulations.
More informationThe Triple Threat. Cardiac Care in the NT Annual Workshop 2017 is proudly supported by:
The Triple Threat DR KELUM PRIYADARSHANA FRACP CONSULTANT NEPHROLOGIST ROYAL DARWIN HOSPITAL Cardiac Care in the NT Annual Workshop 2017 is proudly supported by: Pathogenesis Diabetes CKD CVD Diabetic
More informationFETAL ECHO IN TWIN PREGNACY: MONOCHORIONIC TWINS DELHI CHILD HEART CENTER & INDRAPRASTHA APOLLO HOSPITAL NEW DELHI
FETAL ECHO IN TWIN PREGNACY: MONOCHORIONIC TWINS DELHI CHILD HEART CENTER & INDRAPRASTHA APOLLO HOSPITAL NEW DELHI Scope of this talk Twin to Twin Transfusion TRAP Sequence Congenital Heart Defects in
More informationThe Heart of a Cyclist Insights from Sports Cardiology. Michel Accad, MD February 21, 2018 UCSF Mini Medical School
The Heart of a Cyclist Insights from Sports Cardiology Michel Accad, MD February 21, 2018 UCSF Mini Medical School Lecture outline: WARNING: Not a lecture about how to boost your performance! Preliminary
More informationTODAY S TOPIC Blood Pressure & Pulse Wave Measurement Combined in One Procedure Re-classification of Risk Patients
CARDIOVASCULAR TECHNOLOGY AND INDICATION SERVICE TODAY S TOPIC Blood Pressure & Pulse Wave Measurement Combined in One Procedure Re-classification of Risk Patients SERIES Hypertension Management in the
More informationRole of High-sensitivity C-reactive Protein as a Marker of Inflammation in Pre-dialysis Patients of Chronic Renal Failure
ORIGINAL ARTICLE JIACM 2009; 10(1 & 2): 18-22 Abstract Role of High-sensitivity C-reactive Protein as a Marker of Inflammation in Pre-dialysis Patients of Chronic Renal Failure N Nand*, HK Aggarwal**,
More informationCardiovascular disease is highly prevalent at all stages of
Anemia and the Heart in Chronic Kidney Disease Nadia Zalunardo* and Adeera Levin Cardiovascular disease is highly prevalent at all stages of chronic kidney disease (CKD) and is the leading cause of morbidity
More informationAssociation of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients
Kidney International, Vol. 65 (2004), pp. 626 633 Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients SUYING LI and ALLAN J. COLLINS Nephrology
More informationChanges in Blood Pressure and Vascular Physiology: Markers for Cardiovascular Disease
...SYMPOSIUM PROCEEDINGS... Changes in Blood Pressure and Vascular Physiology: Markers for Cardiovascular Disease Based on a presentation by Joseph L. Izzo, Jr., MD Presentation Summary Changes in systolic
More information10/8/2018. Lecture 9. Cardiovascular Health. Lecture Heart 2. Cardiovascular Health 3. Stroke 4. Contributing Factor
Lecture 9 Cardiovascular Health 1 Lecture 9 1. Heart 2. Cardiovascular Health 3. Stroke 4. Contributing Factor 1 The Heart Muscular Pump The Heart Receives blood low pressure then increases the pressure
More informationCoronary artery calcification and aortic pulse wave velocity in chronic kidney disease patients
Kidney International, Vol. 65 (2004), pp. 1790 1794 Coronary artery calcification and aortic pulse wave velocity in chronic kidney disease patients ALI A. HAYDAR, ADRIAN COVIC, HELEN COLHOUN, MICHAEL RUBENS,
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 4,000 116,000 120M Open access books available International authors and editors Downloads Our
More informationWhen should you treat blood pressure in the young?
ESC Stockholm - Dilemmas in Cardiovascular Disease Prevention in the Young: 30 th August 2010 When should you treat blood pressure in the young? Bryan Williams MD FRCP FAHA FESC Professor of Medicine Department
More informationAssessment of Risk Factors for Cardiovascular Complications in Patients with Chronic Kidney Disease (CKD) Stage III- V before Dialysis
University Heart Journal Vol. 9, No. 1, January 2013 Assessment of Risk Factors for Cardiovascular Complications in Patients with Chronic Kidney Disease (CKD) Stage III- V before Dialysis KHAN MK 1, RASHID
More informationFailing Heart. Cardiac Resynchronization: novel therapy for the
Advanced Studies in Medicine Cardiac Resynchronization: novel therapy for the Failing Heart Module 1: Understanding the Scope of Heart Failure, A Review of the Concepts of Anatomy & Physiology THE JOHNS
More informationPrevalence of anemia and cardiovascular diseases in chronic kidney disease patients: a single tertiary care centre study
International Journal of Advances in Medicine Sathyan S et al. Int J Adv Med. 2017 Feb;4(1):247-251 http://www.ijmedicine.com pissn 2349-3925 eissn 2349-3933 Original Research Article DOI: http://dx.doi.org/10.18203/2349-3933.ijam20170120
More informationProtecting the heart and kidney: implications from the SHARP trial
Cardiology Update, Davos, 2013: Satellite Symposium Protecting the heart and kidney: implications from the SHARP trial Colin Baigent Professor of Epidemiology CTSU, University of Oxford S1 First CTT cycle:
More informationDefinition of Congestive Heart Failure
Heart Failure Definition of Congestive Heart Failure A clinical syndrome of signs & symptoms resulting from the heart s inability to supply adequate tissue perfusion. CHF Epidemiology Affects 4.7 million
More informationThe impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure
Nephrol Dial Transplant (2002) 17: 340 345 The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure Naseem Amin Genzyme Corporation, Cambridge, MA,
More informationBUSINESS. Articles? Grades Midterm Review session
BUSINESS Articles? Grades Midterm Review session REVIEW Cardiac cells Myogenic cells Properties of contractile cells CONDUCTION SYSTEM OF THE HEART Conduction pathway SA node (pacemaker) atrial depolarization
More informationA Study of Clinical Profile in Chronic Kidney Disease with Special Reference to Echo and Electrocardiography
ORIGINAL ARTICLE A Study of Clinical 10.5005/jp-journals-10045-0072 Profile in Chronic Kidney Disease A Study of Clinical Profile in Chronic Kidney Disease with Special Reference to Echo and Electrocardiography
More informationIS PVR THE RIGHT METRIC FOR RV AFTERLOAD?
Echo Doppler Assessment of PVR The Children s Hospital Denver, CO Robin Shandas Professor of Pediatrics, Cardiology Professor of Mechanical Engineering Director, Center for Bioengineering University of
More informationLEFT VENTRICULAR HYPERTROPHY IN AFRICAN BLACK PATIENTS WITH CHRONIC RENAL FAILURE AT FIRST EVALUATION
LEFT VENTRICULAR HYPERTROPHY IN AFRICAN BLACK PATIENTS WITH CHRONIC RENAL FAILURE AT FIRST EVALUATION Objective: Chronic kidney disease (CKD) is a major cause of cardiovascular morbidity and mortality
More informationImproved survival of type 2 diabetic patients on renal replacement therapy in Finland
Nephrol Dial Transplant (2010) 25: 892 896 doi: 10.1093/ndt/gfp555 Advance Access publication 21 October 2009 Improved survival of type 2 diabetic patients on renal replacement therapy in Finland Marjo
More informationDiastolic Heart Failure. Edwin Tulloch-Reid MBBS FACC Consultant Cardiologist Heart Institute of the Caribbean December 2012
Diastolic Heart Failure Edwin Tulloch-Reid MBBS FACC Consultant Cardiologist Heart Institute of the Caribbean December 2012 Disclosures Have spoken for Merck, Sharpe and Dohme Sat on a physician advisory
More information